Globally recognized leader in early-phase oncology clinical development and experimental therapeuticsStrengthens strategic ...
Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and ...
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a ...
The gut microbiome is no longer viewed as a mere spectator in cancer development – it is increasingly recognized as a key ...
Cancer remains notoriously difficult to treat, partly because tumors co‑opt their surrounding environment, including the ...
Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical ...
A newly found chain-reaction phase change in 2D MoTe2 lowers energy barriers, enabling faster control of electronic and ...
Anthropic’s new Claude research reveals a hidden internal “global workspace” that resembles human conscious processing, ...
New Preclinical Data Demonstrate Favorable Oral Bioavailability, Robust Brain Penetration and Liver Exposure with ...
Radiation therapy remains a central modality in cancer treatment, but normal-tissue toxicity and long-term stochastic effects ...
Researchers from UNSW Sydney have built the first artificial protein motor capable of taking controlled, directional steps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results